PepGen narrows Q2 net loss to $17.8 million; DSMB backs highest dose cohort
PepGen reported a second-quarter 2026 net loss of $17.8 million, or $(0.26) per share, down from $23.1 million, or $(0.70) per share, a year earlier, as research and development expenses fell to $12.5 million from $18.4 million. An independent Data and Safety Monitoring Board recommended advancing the Phase 2 FREEDOM2-DM1 study to its 12.5 mg/kg cohort and raising the open-label extension dose from 5 mg/kg to 10 mg/kg. The company had $117.2 million in cash as of June 30, 2026, which it says is enough to fund operations into the fourth quarter of 2027.
Key points
- Net loss of $17.8 million, or $(0.26) per share, for the quarter ended June 30, 2026, versus $23.1 million, or $(0.70) per share, a year earlier
- Research and development expenses were $12.5 million, down from $18.4 million; general and administrative expenses rose to $6.4 million from $5.5 million
- Cash, cash equivalents and marketable securities were $117.2 million at June 30, 2026, down from $148.5 million at December 31, 2025
- The 10 mg/kg FREEDOM2 cohort data is expected in November 2026, and 12.5 mg/kg cohort results are expected in the first half of 2027
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.